Coll de Tuero G, Foguet-Boreu Q, Rodríguez-Poncelas A, Sanmartín-Albertos M, Sáez-Zafra M, Barceló-Rado M A
Ambito de Atención Primaria, ICS, Girona, Spain.
Aten Primaria. 2006 Apr 15;37(6):355-9. doi: 10.1157/13086703.
There are no existing studies that appraise cardiovascular morbidity-mortality in patients diagnosed with isolated clinical hypertension (HCA) through self-measurement of blood pressure (AMPA).
To find the prognostic value of AMPA for diagnosing HCA, by means of assessment of cardiovascular morbidity-mortality in clinical and out-patient measurement (MAPA) of blood pressure.
Prospective study with 3 cohorts: 1) hypertense patients; 2) patients with HCA, and 3) patients with normal blood pressure. All patients seen at 14 primary care centres with newly diagnosed essential hypertension will be included. AMPA will distinguish who has HCA. One in every four patients will have a MAPA. In parallel, a cohort of people with normal pressure will be selected. The follow-up period will be 3 years. We calculate that the sample needed will be 1400 people. The main measurements will be the prevalence of lesions in the target organ and mortality due to cardiovascular disease in the 3 cohorts. The prevalence of HCA will also be worked out.
If the AMPA technique is shown to be as valid as MAPA, then it can be used to diagnose HCA, which would be beneficial because of its accessibility, lower cost and greater comfort for patients.
目前尚无研究通过自测血压（AMPA）对诊断为单纯临床高血压（HCA）的患者进行心血管病发病率-死亡率评估。
通过评估临床和门诊血压测量（MAPA）中的心血管病发病率-死亡率，找出AMPA对诊断HCA的预后价值。
对3个队列进行前瞻性研究：1）高血压患者；2）HCA患者；3）血压正常的患者。将纳入在14个初级保健中心就诊的所有新诊断为原发性高血压的患者。AMPA将区分出患有HCA的患者。每4名患者中就有1名会进行MAPA。同时，将选择一组血压正常的人群。随访期为3年。我们计算出所需样本量为1400人。主要测量指标将是3个队列中靶器官病变的患病率和心血管疾病死亡率。还将计算HCA的患病率。
如果AMPA技术被证明与MAPA一样有效，那么它可用于诊断HCA，这将是有益的，因为其具有可及性、成本较低且患者舒适度更高。
